Newsroom

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On February 6, 2026, Hub Group shares fell sharply, aft...

KUWAIT CITY--(BUSINESS WIRE)--DCO concludes 5th General Assembly with adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025. Integer is a medical device contract manufacturer. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Integer Holdings Corpora...

HYDERABAD, India--(BUSINESS WIRE)--Tanla today announced a major impact milestone for Wisely Ai, following an impact celebration event hosted by Indosat Ooredoo Hutchison in Indonesia....

PALO ALTO, Calif.--(BUSINESS WIRE)--Honda Motor Co., Ltd. and Mythic announce a joint development agreement in which Honda R&D Co. Ltd., the R&D subsidiary of Honda, will license Mythic’s Analog Processing Unit (APU) technology and the companies will co-develop an automotive-grade AI SOC for deployment in Honda’s next-generation software-defined vehicles (SDVs) by the late 2020s/early 2030s. In line with Honda’s safety approach, Mythic’s intelligent, ultra-efficient analog compute-in-me...

ニューオーリンズ＆ヨクネアム（イスラエル）--(BUSINESS WIRE)--（ビジネスワイヤ） -- 能動血管内デバイスのリーディングカンパニーであるラピッド・メディカル™は、DISTALS多施設共同無作為化対照試験からの最新の結果を発表しました。この試験では、中等度血管閉塞（MVO）脳卒中において、TIGERTRIEVER™ 13が内科的治療と比較して、優れた脳組織再灌流と安全性プロファイルを実現できることが示されました。この結果は、2026年国際脳卒中会議（ISC）のメイン閉会セッションで発表されました。 トップライン結果では、TIGERTRIEVER™ 13を適用した群は、薬物療法群と比較して症候性頭蓋内出血（sICH）を伴わない再灌流成功率が3倍高く、86.3%対27.7%（p < 0.001）との結果となりました。特筆すべきは、TIGERTRIEVER 13を投与された無作為化治療群では、sICHイベントが報告されなかったことです。比較においては、静脈内血栓溶解療法のみで報告されたsICH発生率は、最近の試験では2～6%と高くなっています1,2,3。 DISTAL...

LA NOUVELLE-ORLÉANS et YOKNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, entreprise leader dans le développement de dispositifs endovasculaires actifs, a annoncé aujourd'hui les résultats préliminaires de l'essai multicentrique randomisé contrôlé DISTALS. Ces résultats montrent que le dispositif TIGERTRIEVER™ 13 permet une reperfusion cérébrale supérieure et présente un excellent profil d'innocuité par rapport à la prise en charge médicale des AVC par occlusion des vaisseaux de moyen calibre (O...

NEW ORLEANS e YOKNEAM, Israele--(BUSINESS WIRE)--Rapid Medical™, un’azienda leader nello sviluppo di dispositivi endovascolari attivi, oggi ha annunciato i risultati “late-breaking” del trial clinico controllato, randomizzato e multicentrico DISTALS, che dimostrano che TIGERTRIEVER™ 13 ha ottenuto una riperfusione superiore del tessuto cerebrale, con un eccellente profilo di sicurezza, rispetto alla gestione medica nell’ictus da occlusione dei medi vasi. I risultati sono stati presentati durant...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of SunOpta Inc. (NASDAQ: STKL) to Refresco for $6.50 per share in cash. Halper Sadeh encourages SunOpta shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether SunOpta and its board of directors violated the federa...

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ:RR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 3, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadli...